Potential cardioprotective effects of Amentoflavone in doxorubicin-induced cardiotoxicity in mice - 10/09/22
, Thanaa A. El-Masry b , Walaa A. Negm c, ⁎, 1 , Aya H. El-Kadem b, ⁎, 2 Abstract |
Doxorubicin (DOX) is an available chemotherapeutic drug for treating various tumors. However, its effectiveness is limited by cardiotoxicity. Amentoflavone (AMF), a natural biflavonoid separated from Cycas thouarsii ethyl acetate fraction, displays promising anticancer, anti-inflammatory, and antioxidant effects. Thus, our research aims to explore whether AMF could boost cardioprotective effects against DOX cardiotoxicity and reveal the potential underlying mechanisms of cardioprotection. Mice were classified into four groups; Normal control, Untreated DOX group, and DOX groups treated with AMF (40 and 80 mg/kg, respectively) intraperitoneal injection daily for four days before doxorubicin administration and for additional three days following DOX administration to assess cardiotoxicity. Echocardiography showed that AMF 80 treated group was protected from DOX cardiotoxicity. Additionally, it alleviated histopathological structural alterations and effectively restored heart weight and body weight ratio. These effects were confirmed biochemically by a substantially reduced serum creatine kinase-MB (CK-MB) and aspartate aminotransferase (AST) levels. AMF effectively restored nuclear respiratory factor-1(NRF-1), mitochondrial transcription factor A (TFAM), and normalized heat shock protein − 27(HSP-27) expression levels compared to the DOX group. Moreover, AMF mitigated oxidative stress conditions and significantly suppressed NADPH oxidase (NOX) expression levels. It also showed significant anti-inflammatory effects via suppressing interleukin-6 (IL-6) expression and decreasing nuclear factor Kabba B (NF-κb) immune-staining. In addition, AMF markedly reduced FAS ligand (FASL) expression and p53 immune staining in cardiac tissue. This study is the first for the in vivo potential beneficial effects of AMF against acute DOX cardiotoxicity, possibly via exerting antioxidant, anti-inflammatory, and anti-apoptotic effects and restoring mitochondrial function.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Doxorubicin-induced cardiotoxicity by several mechanisms including NOX up regulation resulting in oxidative stress, suppression of HSP-27 leading to apoptosis and oxidative stress, activation of NFĸB, FASL, P53 inducing myocardial apoptosis, and down-regulation of mitochondrial genes NRF-1, TFAM leading to mitochondrial dysfunction. All these events eventually induced myocardial damage. AMF prior treatment safeguards against DOX cardiotoxicity by modulation of all these pathways and preserving mitochondrial function. Amentoflavone (AMF), FAS ligand (FASL), Heat shock protein-27 (HSP-27), NADPH oxidase (NOX), Nuclear factor Kabba B (NFĸB), Nuclear respiratory factor-1(NRF-1) and Mitochondrial transcription factor A(TFAM).
Doxorubicin-induced cardiotoxicity by several mechanisms including NOX up regulation resulting in oxidative stress, suppression of HSP-27 leading to apoptosis and oxidative stress, activation of NFĸB, FASL, P53 inducing myocardial apoptosis, and down-regulation of mitochondrial genes NRF-1, TFAM leading to mitochondrial dysfunction. All these events eventually induced myocardial damage. AMF prior treatment safeguards against DOX cardiotoxicity by modulation of all these pathways and preserving mitochondrial function. Amentoflavone (AMF), FAS ligand (FASL), Heat shock protein-27 (HSP-27), NADPH oxidase (NOX), Nuclear factor Kabba B (NFĸB), Nuclear respiratory factor-1(NRF-1) and Mitochondrial transcription factor A(TFAM).ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | Amentoflavone mitigates Doxorubicin cardiotoxicity. |
• | Amentoflavone restores cardiac HSP 27 levels. |
• | Amentoflavone restores mitochondrial genes NRF-1 and TFAM expression levels. |
• | Amentoflavone has promising antioxidant and apoptotic effects. |
Keywords : Doxorubicin, Cardiotoxicity, Cycas thouarsii, HSP-27, NOX, Apoptosis
Plan
Vol 154
Article 113643- octobre 2022 Retour au numéro
Article précédent
- Inhibition of oxidative stress, IL-13, and WNT/β-catenin in ovalbumin-sensitized rats by a novel organogel of Punica granatum seed oil saponifiable fraction
- Nadia Z. Shaban, Alaa S. Mohammed, Marwa M. Abu-Serie, Adham M. Maher, Noha H. Habashy
- Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation
- Fangyuan Chen, Lei Ma, Guihui Cai, Junyuan Tang, Yi Wang, Qingmei Liu, Xiawen Liu, Ning Hou, Zhi Zhou, Wei Yi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?